Nexentis Technologies子公司Mitocarex完成人类Slc转运蛋白的全面分析

美股速递
Jun 17

Nexentis Technologies Inc的子公司Mitocarex宣布,已完成对人类溶质载体(Slc)转运蛋白家族的全面分析。这项研究旨在深入探索该蛋白家族在细胞代谢和药物转运中的关键作用,为后续的药物靶点发现和新型疗法开发奠定重要的科学基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10